A pooled analysis of the cardiac events in the trastuzumab adjuvant trials

ConclusionOne year of trastuzumab increases the risk of cardiac events, though most consist of asymptomatic or mildly symptomatic LVEF drops. Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Trastuzumab-associated cardiotoxicity is the main cause of discontinuation and further research is needed to individualize prevention and management.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research